EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer’s disease therapy

Md Habib Ullah Masum iD, Syed Mohammad Lokman, Rehana Parvin, Md Shahidur Rahman, Erfanul Haq Chowdhury, Kazi Chamonara, Salma Chowdhury, Ahmad Abdullah Mahdeen, Mst Mitu Khatun

PLOS One · 16.06.2025 · 20 (6) · e0326219

DOI: 10.1371/journal.pone.0326219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.06.2025. Verfasst von Md Habib Ullah Masum und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomics and Bioinformatics, Faculty of Biotechnology and Genetic Engineering, Chattogram Veterinary and Animal Sciences University, Kh…. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Fungi. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is a major global health concern, affecting millions worldwide, with its prevalence expected to triple by 2050. Despite the widespread use of traditional drugs like cholinesterase inhibitors and NMDA receptor antagonists, their limited effectiveness requires innovative therapeutic approaches. This work used Computer-Aided Drug Design (CADD) to renovate AD therapies aimed at both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) using fungal secondary metabolites. Subsequent pharmacokinetic profiles indicated that all metabolites had significant gastrointestinal absorption, blood-brain barrier permeability, and adherence to Lipinski’s Rule of Five, suggesting favourable drug-like properties. Furthermore, these metabolites exhibited little toxicity, except for Lovastatin, which indicated possible carcinogenicity. Molecular docking revealed three main candidates—Fumitremorgin C, Hericenone J, and Lovastatin—with notable binding affinities for AChE and BuChE. Consequently, the Fumitremorgin C showed the highest affinity for AChE (−10.0 kcal/mol), but Hericenone J showed enhanced inhibition of BuChE (−9.2 kcal/mol), suggesting its potential use in advanced stages of AD. Molecular dynamics simulations spanning 100 ns validated the stability of enzyme-ligand complexes, with Hericenone J exhibiting the greatest stability, low RMSD, and strong hydrogen bond interactions. The RMSF analysis further demonstrated that Hericenone J preserved structural integrity, whereas ROG and SASA values validated its compactness and stability. As determined by binding energy calculations, Hericenone J had the most inhibitory potential, followed by Lovastatin. However, Hericenone J’s constant adoption of low-energy conformations, as shown by the principal component and Gibbs free energy analyses, suggested robust and stable interactions with both cholinesterases. With its superior pharmacokinetic profiles, significant binding affinity, and high stability, Hericenone J is the most promising dual cholinesterase inhibitor. These results support the notion that Hericenone J might be an effective treatment for AD if subjected to more preclinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinesterase InhibitorsAlzheimer DiseaseFungiMolecular Docking SimulationHumansButyrylcholinesteraseMolecular Dynamics SimulationAcetylcholinesteraseAnimalsDrug DesignLovastatin

Substanzen

Cholinesterase InhibitorsButyrylcholinesteraseAcetylcholinesteraseLovastatin

Autor:innen und Institutionen

  • Department of Genomics and Bioinformatics, Faculty of Biotechnology and Genetic Engineering, Chattogram Veterinary and Animal Sciences University, Khulshi, Bangladesh.
  • Asian University for Women (AUW), Chattogram, Bangladesh.
  • Department of Pathology and Parasitology, Faculty of Veterinary Medicine, Chattogram Veterinary and Animal Sciences University, Khulshi, Bangladesh.
  • Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • Lovely Professional University, Phagwāra, Punjab, India.
  • Department of Environmental Biotechnology, Faculty of Biotechnology and Genetic Engineering, Chattogram Veterinary and Animal Sciences University, Khulshi, Bangladesh.

ORCID-Profile: Md Habib Ullah Masum

Zitieren

APA

Masum, M. H. U., Lokman, S. M., Parvin, R., Rahman, M. S., Chowdhury, E. H., Chamonara, K., Chowdhury, S., Mahdeen, A. A., & Khatun, M. M. (2025). Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer’s disease therapy. PLOS One, 20(6), e0326219. https://doi.org/10.1371/journal.pone.0326219

Vancouver

Masum MHU, Lokman SM, Parvin R, Rahman MS, Chowdhury EH, Chamonara K, et al. Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer’s disease therapy. PLOS One. 2025;20(6):e0326219. doi:10.1371/journal.pone.0326219

BibTeX
@article{Masum2025,
  author = {Masum, Md Habib Ullah and Lokman, Syed Mohammad and Parvin, Rehana and Rahman, Md Shahidur and Chowdhury, Erfanul Haq and Chamonara, Kazi and Chowdhury, Salma and Mahdeen, Ahmad Abdullah and Khatun, Mst Mitu},
  title = {Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer’s disease therapy},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0326219},
  doi = {10.1371/journal.pone.0326219}
}
Kostenlos starten →